Long COVID in children emerged as a clinical concern later in the pandemic than in adults, in part because children's acute COVID-19 illness is typically mild. The assumption that mild acute illness would not produce prolonged sequelae has been challenged by clinical experience and, subsequently, by population data. Understanding what long COVID in children typically looks like – as distinct from prolonged symptoms from other causes – and what supports recovery is important for families navigating a picture that is still developing.
The research base is improving but remains limited compared to adult long COVID. What is clear is that some children do experience genuine, prolonged symptoms following COVID-19 that affect their daily functioning, and that these children and their families deserve to be taken seriously and to receive appropriate support.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers post-viral conditions in children.
Defining Long COVID in Children
Long COVID (also called post-COVID condition) is defined by the World Health Organisation as symptoms that persist or develop following SARS-CoV-2 infection, typically 12 or more weeks after the initial illness, that cannot be explained by another diagnosis. The UK NICE, Scottish Intercollegiate Guidelines Network (SIGN), and Royal College of General Practitioners (RCGP) produced joint guidance in 2020 and updated it in 2022, using the same 12-week threshold.
The symptoms most commonly reported in children with long COVID are fatigue (present in the large majority of cases), headache, difficulty concentrating (cognitive symptoms described as "brain fog"), sleep difficulties, abdominal pain, and breathlessness. Joint pain, chest pain, and mood difficulties (anxiety and depression) are also reported. Less commonly, children report sensory symptoms, palpitations, and orthostatic intolerance (dizziness and symptoms on standing) suggesting autonomic dysfunction – the overlap with POTS is meaningful.
Prevalence and Study Challenges
Estimating the prevalence of long COVID in children is genuinely difficult. Studies have used different case definitions, different methods of identifying COVID-19 infection (positive test vs antibody evidence vs self-report), different symptom thresholds, different follow-up periods, and – critically – different comparison groups (some studies lack a control group of children who did not have COVID-19, making it impossible to attribute persistent symptoms specifically to infection rather than to pandemic-era factors such as lockdown, school closure, and social isolation, which themselves affected children's wellbeing).
The OpenSAFELY study and Office for National Statistics surveys provide some of the best UK data. ONS surveys documented that around 2% of children aged 2-11 and 4-7% of children aged 12-16 reported symptoms lasting more than 12 weeks after COVID-19 infection; however, comparison groups showed elevated persistent symptoms in children who had not tested positive for COVID-19, suggesting that some proportion of "long COVID" symptoms reflects pandemic-era adversity rather than post-infection sequelae specifically.
Research from Great Ormond Street Hospital and UCL, published in The Lancet Child and Adolescent Health (2022), found that long COVID in children was associated with specific patterns of symptoms, particularly fatigue and cognitive symptoms, that were more specific to infection than lockdown-related effects.
Overlap with ME/CFS
The symptom overlap between long COVID and ME/CFS is substantial. Post-exertional malaise (PEM) – the characteristic worsening of symptoms after physical or cognitive exertion that is the defining feature of ME/CFS – is present in a significant proportion of children with long COVID and is particularly important to identify, because it determines management. Children with significant PEM should not be pushed to "push through" fatigue, as this can lead to relapse and worsening.
NICE's guidance on long COVID in children explicitly cross-references the ME/CFS guideline, acknowledging the mechanistic and management overlap. For children who meet ME/CFS diagnostic criteria following COVID-19, ME/CFS management guidance applies.
PIMS-TS / MIS-C
Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS, called MIS-C in the USA) is a distinct condition from long COVID. PIMS-TS is an acute, rare, severe inflammatory condition occurring 2-6 weeks after COVID-19 infection, characterised by fever, rash, conjunctivitis, gastrointestinal symptoms, and cardiovascular involvement (including coronary artery dilatation). It typically presents dramatically with a clearly unwell child requiring hospitalisation. PIMS-TS is not the same as prolonged mild symptoms; the distinction is clinically important.
Management
There are no licensed treatments for long COVID in children, and the evidence base for management approaches remains limited. Management parallels ME/CFS guidance:
Energy management (pacing): identifying the activity level at which symptoms don't worsen and building from a stable baseline rather than pushing through fatigue. This is particularly important for children with PEM.
Symptom-specific support: headache management, sleep hygiene, orthostatic intolerance management (hydration, salt, compression, and where needed, medication for confirmed POTS).
Maintaining education: flexible school attendance, reduced timetables, rest access, and written backup to verbal instructions are practical adjustments. Virtual or partial attendance may bridge a period of recovery. For children significantly affected, an EHC plan may be appropriate.
Psychological support: the uncertainty and impact of long COVID is distressing, and anxiety, depression, and adjustment difficulties are common in affected children and their families. Psychological support should be part of the management, not an afterthought.
The NHS has established Long COVID clinics and assessment services for children in some regions. Referral is via GP. Long COVID Kids and Long COVID Support provide peer support and information for families.
Key Takeaways
Long COVID in children – persistent symptoms following COVID-19 infection that last beyond 12 weeks – is more common than initially recognised, though the picture is complex and contested. Estimates of prevalence in children vary widely depending on case definition and study design; population-based studies including the Office for National Statistics surveys have documented persistent symptoms in around 2-7% of children following COVID-19 infection. The most common symptoms are fatigue, headache, difficulty concentrating ('brain fog'), and abdominal pain. Most children recover over months; a minority have significant, prolonged impairment. Management parallels ME/CFS management, emphasising energy management and maintaining function.
